KOKaren O'DWyer

Karen O'DWyer

*This is an algorithmically generated author record based on publicly available information.

Karen O'DWyer has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Innovative roadmaps for sustainable antimicrobial resistance interventions

    by Gianmarco Gasperini, Silvia Rossi Paccani, Karen O’DWyer, David M. Aanensen, Darius Armstrong-James, Francesco Berlanda Scorza, David E. Bloom, Christopher J. Burns, Madalina Elena Carter-Timofte, Felipe J. Colón-González, et al.

    Integrated strategies to combat antibiotic-resistant bacteria and fungi require innovative commercial models, new discovery platforms, standardized genomic surveillance, and streamlined clinical trials. Machine learning and other new technologies will accelerate the development of diagnostics and therapeutics (small molecules, antibodies, and vaccines) to combat antimicrobial resistance. Next-generation approaches should align societal impact with investment to ensure rapid global public health gains.

  • Open Access

    Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax

    by Jamese J. Hilliard, Charles Jakielaszek, Frank Mannino, Mohammad Hossain, Lian Qian, Cindy Fishman, Samandra Demons, Jeremy Hershfield, Carl Soffler, Riccardo Russo, et al.

    Bacillus anthracis is a Gram-positive Centers for Disease Control and Prevention category “A” biothreat pathogen. Without early treatment, inhalation of anthrax spores with progression to inhalational anthrax disease is associated with high fatality rates. Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is being evaluated for use against biothreat and conventional pathogens. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode and has in vitro activity against a collection of B. anthracis isolates including antibacterial-resistant strains, with the MIC 90 ranging from 0.5 to 1 µg/mL. In vivo activity of gepotidacin was also evaluated in the New Zealand White rabbit model of inhalational anthrax. The primary endpoint was survival, with survival duration and bacterial clearance as secondary endpoints. The trigger for treatment was the presence of anthrax protective antigen in serum. New Zealand White rabbits were dosed intravenously for 5 days with saline or gepotidacin at 114 mg/kg/d to simulate a dosing regimen of 1,000 mg intravenous (i.v.) three times a day (TID) in humans. Gepotidacin provided a survival benefit compared to saline control, with 91% survival ( P -value: 0.0001). All control animals succumbed to anthrax and were found to be blood- and organ culture-positive for B. anthracis . The novel mode of action, in vitro microbiology, preclinical safety, and animal model efficacy data, which were generated in line with Food and Drug Administration Animal Rule, support gepotidacin as a potential treatment for anthrax in an emergency biothreat situation.


  • Open Access

    Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge

    by Charles Jakielaszek, Jamese J. Hilliard, Frank Mannino, Mohammad Hossain, Lian Qian, Cindy Fishman, Ying-Liang Chou, Lisa Henning, Joseph Novak, Samandra Demons, et al.

    Francisella tularensis ( F. tularensis ) is a Centers for Disease Control (CDC) category “A” Gram-negative biothreat pathogen. Inhalation of F. tularensis can cause pneumonia and respiratory failure and is associated with high mortality rates without early treatment.


  • Gepotidacin is efficacious in a nonhuman primate model of pneumonic plague

    by Charles Jakielaszek, Mohammad Hossain, Lian Qian, Cindy Fishman, Katherine Widdowson, Jamese J. Hilliard, Frank Mannino, Aparna Raychaudhuri, Elisabeth Carniel, Samandra Demons, et al.

    Gepotidacin is a first-in-class triazaacenaphthylene antibacterial agent that selectively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has the potential to treat a number of bacterial diseases. Development of this new agent to treat pneumonic plague caused by Yersinia pestis depends on the U.S. Food and Drug Administration Animal Rule testing pathway, as testing in humans is not feasible. Here, preclinical studies were conducted in the African green monkey (AGM) inhalational model of pneumonic plague to test the efficacy of gepotidacin. AGMs infected with Y. pestis were dosed intravenously with gepotidacin (48, 36, or 28 milligrams/kilogram per day) for 10 days to provide a plasma concentration that would support a rationale for a 1000 mg twice or thrice daily intravenous dose in humans or saline as a control. The primary end point was AGM survival with predefined euthanasia criteria. Secondary end points included survival duration and bacterial clearance. Gepotidacin showed activity in vitro against diverse Y. pestis isolates including antibiotic-resistant strains. All control animals in the inhalational plague studies succumbed to plague and were blood culture and organ culture positive for Y. pestis . Gepotidacin provided a 75 to 100% survival benefit with all dose regimens. All surviving animals were blood culture and organ culture negative for Y. pestis . Our randomized, controlled efficacy trials in the AGM pneumonic plague nonhuman primate model together with the in vitro Y. pestis susceptibility data support the use of gepotidacin as a treatment for pneumonic plague caused by Y. pestis .